When a customer publishes an FDA 510(k) submission summary that names your product as a software-component, a predicate-device reference, a substantial-equivalence-comparison dependency, or a cybersecurity-controls reference, ships an FDA De Novo classification request decision summary that names your product among the cited risk-mitigation dependencies, releases an EU MDR (Medical Device Regulation 2017/745) CE certificate technical-documentation summary that names your product among the in-scope software-as-a-medical-device or device-software-functions components, maintains a Japan PMDA Shōnin (approval) or Ninshō (certification) public-database disclosure that names your product, holds a Health Canada Medical Device Licence (MDL) public listing that names your product, or publishes a UKCA conformity-assessment-body technical-file summary that names your product in the cybersecurity-and-software-life-cycle disclosure scope, they have left a category of endorsement that almost no marketing-elicited testimonial can replicate. The medical-device regulatory disclosure has been written under the regulatory-clearance commitment of an FDA-reviewer-evaluated 21 CFR Part 807 Subpart E pathway, an EU MDR Annex II technical-documentation framework, a Japan PMD Act Article 23 review, a Health Canada Class II/III/IV device-licence framework, or a UK MDR 2002 conformity-assessment framework, archived permanently in agency public-disclosure databases like the FDA 510(k) Premarket Notification Database, the FDA De Novo Pathway Database, the EUDAMED EU MDR registry, the PMDA Iyakuhin Iryōkiki Sōgō Kikō Kensaku database, and Health Canada's Medical Devices Active Licence Listing where any future safety officer, regulator, customer, competing manufacturer, or post-market-surveillance auditor can retrieve it, scrutinized by independent FDA Office of Device Evaluation reviewers and EU notified bodies who have direct regulatory-enforcement and accreditation-renewal incentives to dispute any inaccuracy, and frequently re-referenced in subsequent FDA Medical Device Reporting (MDR) adverse-event filings, EU MDR Field Safety Notices, post-market surveillance reports, and recall classification decisions for years after the original clearance. The medical-device regulatory disclosure carries the customer's regulatory-affairs testimony, the FDA-reviewer or notified-body signature carries the regulatory-clearance ratification, and the surrounding context establishes that the disclosure entry was written under one of the most procedurally constrained public-regulatory-disclosure environments any customer-facing organization encounters.
Almost no developer-tools, security-platform, observability, infrastructure-platform, or B2B SaaS vendor with medical-device-manufacturer customers systematically extracts product mentions from public FDA 510(k), FDA De Novo, EU MDR, Japan PMDA, Health Canada MDL, and UKCA medical-device regulatory archives. The omission is the natural extension of the same blind spots we documented in our SBOM and VEX extraction guide, our SOC 2 and ISO 27001 extraction guide, our bug bounty extraction guide, our SEC filing extraction guide, and our patent filing extraction guide. SBOM and VEX attestations cover supply-chain-security-attested cryptographic-component mentions. SOC 2 and ISO 27001 attestations cover trust-services-attested compliance mentions. Bug bounty disclosures cover researcher-attested security-program mentions. SEC filings cover Sarbanes-Oxley-attested risk-factor mentions. Patent filings cover USPTO-examiner-attested prior-art-cited mentions. Medical-device regulatory content covers FDA-reviewer-cleared, notified-body-CE-marked, regulator-archive-permanent, post-market-surveillance-load-bearing, patient-safety-anchored product mentions made under the most procedurally constrained public-regulatory-clearance environment any customer-facing organization publishes into — a pillar of the structurally durable public corpus that no other extraction surface can replicate, and the only one where the customer's testimony has been tied specifically to a regulatory-clearance pathway under FDA Quality System Regulation 21 CFR Part 820 and EU MDR Annex IX Quality Management System requirements that the customer's market-access revenue actively depends on as a continuing regulatory-compliance contract.
This guide describes the extraction workflow for the FDA 510(k), FDA De Novo, EU MDR, Japan PMDA, Health Canada MDL, and UKCA medical-device regulatory disclosure corpus.
Why an FDA 510(k) or EU MDR CE marking mention beats almost every marketing-elicited testimonial
An FDA 510(k), FDA De Novo, EU MDR, Japan PMDA, Health Canada MDL, or UKCA medical-device regulatory mention is a category of endorsement that has passed through filters no marketing-elicited testimonial encounters. Seven properties stack to make it one of the most adversarially credible regulatory-clearance endorsement formats in modern B2B marketing.
First, the disclosure has been written under a regulatory-clearance framework the customer has committed to follow. Public medical-device regulatory disclosures are governed by published statutes — the FDA 21 CFR Part 807 Subpart E premarket-notification regulation, the FDA Quality System Regulation 21 CFR Part 820, the FDA Cybersecurity Premarket Submissions guidance 2023, the EU MDR (Regulation 2017/745) framework, the EU IVDR (Regulation 2017/746) framework, the EU MDR Annex II technical-documentation requirements, the EU MDR Annex IX quality-management-system requirements, the IEC 62304 medical-device-software life-cycle standard, the IEC 81001-5-1 medical-device-cybersecurity standard, the Japan PMD Act (Pharmaceuticals and Medical Devices Act), and the Health Canada Medical Devices Regulations SOR/98-282. A product mention in a disclosure published under any of these frameworks is being made under a process that the customer has publicly committed to follow as a continuing regulatory-clearance commitment. The regulatory-clearance-framework property is what makes disclosure mentions more credible than mentions in any format that does not pass through a comparable procedural commitment.
Second, the disclosure is archived permanently in agency disclosure databases. Disclosure entries are preserved in the FDA 510(k) Premarket Notification Database, the FDA De Novo Pathway Database, the FDA Premarket Approval (PMA) Database, the EUDAMED EU MDR central registry (Articles 27, 28, 29), the EUDAMED Unique Device Identifier (UDI) database, the PMDA Iyakuhin Iryōkiki Sōgō Kikō Kensaku database, the Health Canada Medical Devices Active Licence Listing, the UK Medicines and Healthcare products Regulatory Agency (MHRA) Public Access Registration Database for Medical Devices (PARMD), and a long tail of agency archives operated under the customer's post-market-surveillance obligations. A product mention in a disclosure publication is therefore preserved across multiple independent agency archives where any future safety officer, regulator, customer, or competing manufacturer can retrieve the disclosure entry and compare it against the customer's current regulatory posture. The cross-agency-permanence property is what makes disclosure mentions more durable than mentions in any format without comparable multi-agency preservation.
Third, the disclosure has been scrutinized by FDA reviewers and EU notified bodies. The FDA Office of Device Evaluation, the FDA Office of Product Evaluation and Quality (OPEQ), the FDA Center for Devices and Radiological Health (CDRH), the EU notified-body community (TÜV SÜD, BSI, DEKRA, DNV, IMQ, KEMA-DEKRA, MEDCERT, Intertek), the Japan PMDA reviewers, the Health Canada Medical Devices Bureau, and the UK MHRA operate an active scrutiny culture in which submissions are reviewed under statutory clearance-decision authority, examined in surveillance and recertification audits, and challenged in regulatory enforcement actions, in FDA Warning Letters and 483 Inspectional Observations, in EU MDR notified-body certificate-suspension actions, on FDA Medical Device Reporting (MDR) and EU MDR Vigilance Reporting public pipelines, and in subsequent post-market-surveillance dispute pipelines. A product mention in a disclosure publication is being read by reviewers who have direct regulatory-enforcement and accreditation-renewal incentives to surface any inaccuracy. The agency-reviewer-scrutiny property is what makes disclosure mentions more adversarially tested than mentions in any format without comparable regulator-community exposure.
Fourth, the disclosure is anchored to an FDA 510(k) number, an EUDAMED UDI-DI, a notified-body certificate number, and a Health Canada MDL number. Disclosure entries are routinely tied to a specific FDA 510(k) K-number (e.g., K-prefixed seven-digit identifier), a specific EUDAMED UDI-DI (Unique Device Identifier — Device Identifier), a specific notified-body certificate number with the notified-body four-digit identification number (e.g., 0123 for TÜV SÜD, 2797 for BSI), a specific Japan PMDA approval-number (Shōnin bangō) or certification-number (Ninshō bangō), and a specific Health Canada MDL number — and the regulatory-identifier becomes a stable reference that the customer's market-access posture depends on as a regulatory-compliance contract. A product mention in a disclosure publication therefore inherits a regulatory-identifier-anchored authority that establishes the mention was made at a precise, agency-cleared point in the customer's regulatory-affairs history. The regulatory-identifier-anchor property is materially stronger than the equivalent on any format without comparable immutable-identifier coverage.
Fifth, the disclosure is cross-referenced by post-market-surveillance and adverse-event-reporting infrastructure. Post-market-surveillance tools — the FDA Manufacturer and User Facility Device Experience (MAUDE) database, the FDA Total Product Life Cycle (TPLC) database, the EUDAMED Vigilance and Post-Market Surveillance module, the PMDA Iyakuhin Iryōkiki Anzensei Jōhō (medical-device-safety-information) database, the Health Canada Canada Vigilance Adverse Reaction Online Database — and adverse-event-reporting tools — the FDA Medical Device Reporting eMDR portal, the EU MDR Manufacturer Incident Report (MIR) portal, the Japan PMDA Yakuji-Kanren-Shidō Kanri System — routinely cross-reference disclosure entries against the customer's adverse-event history and against the customer's post-market-surveillance posture. A product mention in a disclosure publication therefore inherits a post-market-surveillance cross-reference that establishes the mention's authenticity at the highest level of public medical-device regulatory infrastructure. The post-market-surveillance-cross-reference property is what makes disclosure mentions more authority-anchored than mentions in any format without comparable globally indexed safety-surveillance coverage.
Sixth, the disclosure is required by market-access regulation. FDA 510(k) clearances, FDA De Novo classifications, EU MDR CE certificates, Japan PMDA Shōnin approvals, Health Canada MDLs, and UKCA conformity-assessments are mandated for market-access in each respective jurisdiction. A product mention in a market-access-required disclosure is being made under statutory rules the customer cannot opt out of without losing market-access in that jurisdiction. The market-access-mandate property is what makes disclosure mentions more market-access-load-bearing than mentions in any format without comparable regulatory-pathway exposure.
Seventh, the disclosure is actively referenced by the customer's post-market-surveillance pipeline. Subsequent FDA Medical Device Reporting adverse-event filings, EU MDR Field Safety Notices, FDA Recall classifications (Class I, II, III), EU MDR Recall and Vigilance reports, post-market clinical follow-up (PMCF) studies, and periodic safety update reports (PSUR) continuously re-read the disclosure entry as the source-of-truth for the customer's regulatory-clearance scope. A product mention in a disclosure publication is therefore not a one-time clearance but a continuously referenced clearance contract that the customer's post-market-surveillance pipeline is actively responsible for maintaining. The post-market-surveillance-pipeline-reference property is what makes disclosure mentions more operationally load-bearing than mentions in any format without comparable surveillance-pipeline coverage.
The corpus you should be extracting
The FDA 510(k), FDA De Novo, EU MDR, Japan PMDA, Health Canada MDL, and UKCA corpus spans seven primary surfaces. Each surface produces a different disclosure register, a different vocabulary register, and a different testimonial-extraction workflow.
First, the FDA 510(k) Premarket Notification corpus — the FDA 21 CFR Part 807 Subpart E premarket-notification pathway that allows medical-device manufacturers to demonstrate substantial equivalence to a predicate device. FDA 510(k) summaries are published in the FDA 510(k) Premarket Notification Database. A typical FDA 510(k) summary contains a 510(k) Number (K-prefixed seven-digit identifier), a Submitter information block, a Device Name and Device Description, an Indications for Use Statement, a Predicate Device Comparison Table, a Substantial Equivalence Discussion, a Performance Testing section that lists the bench, animal, clinical, and cybersecurity testing performed, and an FDA-issued Substantially Equivalent Decision Letter. The Device Description, the Predicate Device Comparison Table, and the Performance Testing section are the primary product-mention extraction points. The FDA 510(k) cybersecurity submission (per 21 CFR Part 820 and the FDA Cybersecurity Premarket Submissions guidance 2023) is a particularly rich extraction surface where the customer's cybersecurity-controls reference your product as a software-component, an SBOM dependency, a CWE/CVE-mitigation, or a security-monitoring control.
Second, the FDA De Novo classification corpus — the FDA 21 CFR Part 860 Subpart D De Novo pathway that allows medical-device manufacturers to seek classification for a novel device without a legally marketed predicate device. FDA De Novo decision summaries are published in the FDA De Novo Pathway Database. A typical FDA De Novo decision summary contains a De Novo number (DEN-prefixed identifier), a Requester information block, a Device Description, a Proposed Classification recommendation, a Risks-and-Mitigations table that lists the identified risks and the cited mitigations, a Special Controls section that lists the device-type-specific controls, and an FDA-issued Classification Order. The Risks-and-Mitigations table and the Special Controls section are the primary product-mention extraction points. The cybersecurity-risk row and the software-controls row are particularly rich extraction surfaces.
Third, the FDA Premarket Approval (PMA) corpus — the FDA 21 CFR Part 814 premarket-approval pathway for Class III medical devices that requires a full demonstration of safety and effectiveness. FDA PMA summaries of safety and effectiveness data (SSED) are published in the FDA Premarket Approval (PMA) Database. A typical FDA PMA SSED contains a PMA Number (P-prefixed six-digit identifier), a Manufacturer information block, a Device Description, an Indications for Use Statement, a Clinical Investigations section, a Manufacturing Information section, a Software Verification and Validation section, and an FDA-issued Approval Order. The Manufacturing Information section and the Software Verification and Validation section are the primary product-mention extraction points.
Fourth, the EU MDR CE certificate and technical-documentation corpus — the EU MDR (Regulation 2017/745) framework that requires medical-device manufacturers to obtain a CE certificate from a notified body for non-self-certifying device classes (IIa, IIb, III). EU MDR CE certificates and technical-documentation summaries are published on the EUDAMED registry (Articles 27, 28, 29 — UDI database, devices, certificates). A typical EU MDR CE certificate contains a Certificate Number, a Manufacturer information block, a Notified Body identification (four-digit Notified Body Number), a Device classification, an UDI-DI (Unique Device Identifier — Device Identifier), an Annex II technical-documentation reference, an Annex IX quality-management-system reference, and a Certificate validity period. The Annex II technical-documentation reference is the primary product-mention extraction point. The Annex II.6.1 software-life-cycle reference and the Annex I.17.2 cybersecurity reference are particularly rich extraction surfaces where the customer's medical-device-software lifecycle references your product as a software-component, an IEC 62304-conformant dependency, or an IEC 81001-5-1-conformant cybersecurity-control.
Fifth, the Japan PMDA Shōnin (approval) and Ninshō (certification) corpus — the Japan PMD Act (Yakuji-Hō) framework that requires medical-device manufacturers to obtain Shōnin (full approval) or Ninshō (third-party-certification) for non-self-certifying device classes (Class II, III, IV). Japan PMDA decision-summaries are published in the PMDA Iyakuhin Iryōkiki Sōgō Kikō Kensaku database. A typical PMDA Shōnin decision-summary contains a Shōnin number (Shōnin bangō), a Manufacturer information block, a Device Description in Japanese, a Hyōka Shiken (evaluation testing) reference, and a PMDA-issued Shōnin-shō (approval certificate). A typical PMDA Ninshō decision-summary contains a Ninshō number (Ninshō bangō), a Manufacturer information block, a Device Description in Japanese, a Tōroku-Ninshō-Kikan (registered certification body) identification, and a Ninshō-shō (certification certificate). The Hyōka Shiken reference and the Tōroku-Ninshō-Kikan identification are the primary product-mention extraction points.
Sixth, the Health Canada Medical Device Licence (MDL) corpus — the Health Canada Medical Devices Regulations SOR/98-282 framework that requires medical-device manufacturers to obtain a Medical Device Licence (MDL) for Class II, III, or IV devices. Health Canada MDLs are published in the Health Canada Medical Devices Active Licence Listing. A typical Health Canada MDL contains an MDL number, a Manufacturer information block, a Device Identifier, a Device Class (II, III, or IV), an Audit Reference (MDSAP — Medical Device Single Audit Program — certification reference), and a Licence validity status. The MDSAP audit reference is the primary product-mention extraction point.
Seventh, the UKCA conformity-assessment-body technical-file corpus — the UK MDR 2002 framework (post-Brexit) that requires medical-device manufacturers to obtain UKCA marking through a UK conformity-assessment body. UKCA conformity-assessment-body technical-file summaries are published on the UK MHRA Public Access Registration Database for Medical Devices (PARMD). A typical UKCA technical-file summary contains a UK MDR registration number, a Manufacturer information block, a UK Responsible Person designation, a UK Approved Body identification (four-digit identifier), a Device Description, and a Conformity Assessment certificate reference. The Conformity Assessment certificate reference is the primary product-mention extraction point.
The extraction workflow
The workflow has five stages. Each stage is operated by a separate team with separate tooling and separate output-format requirements. The workflow is designed to convert a customer's medical-device regulatory disclosure-archive history into a deployable testimonial library in approximately forty-eight hours per disclosure, with full audit-trail anchoring to the FDA-reviewer and notified-body engagement-reference infrastructure.
Stage one: corpus identification. Identify every FDA 510(k), FDA De Novo, FDA PMA, EU MDR CE certificate, Japan PMDA Shōnin or Ninshō, Health Canada MDL, and UKCA conformity-assessment-body technical-file in which the customer has named your product as a software-component, a predicate-device-cybersecurity reference, a substantial-equivalence dependency, an Annex II software-life-cycle reference, or an MDSAP audit-evidence dependency. Search the FDA 510(k) Premarket Notification Database, the FDA De Novo Pathway Database, and the FDA Premarket Approval (PMA) Database for the customer's manufacturer-name. Search the EUDAMED registry for the customer's UDI-DI scope. Search the PMDA Iyakuhin Iryōkiki Sōgō Kikō Kensaku database for the customer's Japanese-language manufacturer-name. Search the Health Canada Medical Devices Active Licence Listing for the customer's MDL holdings. Search the UK MHRA PARMD for the customer's UKCA registrations. The corpus-identification stage typically surfaces between five and fifty regulatory-disclosure artifacts per established medical-device-manufacturer-active customer. Store each artifact with its regulatory-identifier (510(k) K-number, De Novo DEN-number, PMA P-number, EUDAMED UDI-DI, Notified Body four-digit number, PMDA Shōnin/Ninshō bangō, Health Canada MDL number, UK MDR registration number), its issuance-date, its clearance/approval/certification scope, and its full archived disclosure content.
Stage two: product-mention extraction. Extract every mention of your product from the identified regulatory-disclosure artifacts. The extraction pattern depends on the disclosure format. For FDA 510(k) summaries, scan the Device Description, the Predicate Device Comparison Table, the Performance Testing section, and the Cybersecurity Premarket Submission for software-component-and-cybersecurity-controls matches. For FDA De Novo decision summaries, scan the Risks-and-Mitigations table and the Special Controls section for cybersecurity-risk-row and software-controls-row matches. For FDA PMA SSEDs, scan the Manufacturing Information and Software Verification and Validation sections for software-component matches. For EU MDR CE certificates and technical-documentation summaries, scan the Annex II technical-documentation reference (particularly Annex II.6.1 software-life-cycle reference and Annex I.17.2 cybersecurity reference) for IEC 62304-and-IEC 81001-5-1 software-component-and-cybersecurity-control matches. For Japan PMDA Shōnin and Ninshō decision-summaries, scan the Hyōka Shiken reference and the Tōroku-Ninshō-Kikan identification for software-component matches. For Health Canada MDLs, scan the MDSAP audit reference for audit-evidence-dependency matches. For UKCA technical-file summaries, scan the Conformity Assessment certificate reference for software-component matches. Record the regulatory-identifier, the issuance-date, the clearance/approval/certification scope, the FDA-reviewer or notified-body identification, the surrounding disclosure context, and the published archive URL for each extracted mention.
Stage three: regulatory-identifier-anchor verification. Verify the regulatory-identifier anchor for every extracted mention. Confirm the FDA 510(k) K-number against the FDA 510(k) Premarket Notification Database. Confirm the De Novo DEN-number against the FDA De Novo Pathway Database. Confirm the PMA P-number against the FDA Premarket Approval Database. Confirm the EUDAMED UDI-DI against the EUDAMED registry. Confirm the Notified Body four-digit number against the NANDO (New Approach Notified and Designated Organizations) database. Confirm the PMDA Shōnin bangō or Ninshō bangō against the PMDA Iyakuhin Iryōkiki Sōgō Kikō Kensaku database. Confirm the Health Canada MDL number against the Active Licence Listing. Confirm the UK MDR registration number against the MHRA PARMD. Document the regulatory-identifier-anchor verification for each mention. Mentions without verified regulatory-identifier anchors are downgraded to lower-credibility tier and excluded from market-access-pathway-specific testimonials.
Stage four: market-access-pathway classification. Classify each extracted mention by the market-access pathway it supports. Mentions that appear in FDA 510(k), FDA De Novo, or FDA PMA decisions are classified as US-market-access-load-bearing. Mentions that appear in EU MDR CE certificates are classified as EU-market-access-load-bearing. Mentions that appear in Japan PMDA Shōnin or Ninshō decisions are classified as Japan-market-access-load-bearing. Mentions that appear in Health Canada MDLs are classified as Canada-market-access-load-bearing. Mentions that appear in UKCA conformity-assessments are classified as UK-market-access-load-bearing. The classification determines the appropriate testimonial-deployment surface.
Stage five: testimonial-asset packaging. Package each verified, classified product-mention into a deployable testimonial asset. The testimonial asset contains the customer-company attribution, the customer-product-name reference, the disclosure-format reference (FDA 510(k), FDA De Novo, FDA PMA, EU MDR CE certificate, PMDA Shōnin, PMDA Ninshō, Health Canada MDL, or UKCA conformity-assessment), the regulatory-identifier anchor (K-number, DEN-number, P-number, UDI-DI, Shōnin bangō, MDL number, or UK MDR registration number), the issuance-date, the FDA-reviewer or notified-body identification, the clearance/approval/certification scope, the published archive URL, the market-access-pathway classification, and the regulatory-identifier-anchor verification record. The packaged asset is then released through the proof-deployment pipeline.
Where to deploy medical-device-regulatory-extracted testimonials
Medical-device-regulatory-extracted testimonials deploy most effectively in five surfaces. First, on the medical-device-customer-acquisition page — where medical-device-manufacturer prospects explicitly look for regulatory-clearance evidence and where a US-and-EU-market-access-load-bearing testimonial proves the FDA-510(k)-and-CE-marking-compatibility claim. Second, on the medical-device-cybersecurity page — where medical-device-cybersecurity buyers explicitly look for cybersecurity-controls evidence and where a 510(k)-cybersecurity-submission-archived testimonial proves the IEC 81001-5-1-and-FDA-cybersecurity-program-maturity claim. Third, on the medical-device-software-life-cycle page — where medical-device-software-quality buyers explicitly look for IEC 62304-conformance evidence and where an EU MDR Annex II.6.1-archived testimonial proves the IEC 62304-software-life-cycle-program-maturity claim. Fourth, on the medical-device-post-market-surveillance page — where regulatory-affairs buyers explicitly look for MDSAP and post-market-surveillance evidence and where a Health Canada MDL or PMDA Ninshō-archived testimonial proves the post-market-surveillance-program-maturity claim. Fifth, on the global-market-access page — where medical-device-global-market-access buyers look for multi-jurisdiction evidence and where a multi-jurisdiction-archived testimonial proves the global-regulatory-program-maturity claim.
The asset-packaging stage produces the same artifact for all five surfaces. The deployment stage decides which surface each asset is most credibility-load-bearing for, and applies the corresponding presentation pattern.
What ProofShow automates
ProofShow operates the corpus-identification, the product-mention extraction, the regulatory-identifier-anchor verification, the market-access-pathway classification, and the testimonial-asset packaging stages as a single end-to-end pipeline. Customers connect their FDA 510(k) Premarket Notification, FDA De Novo, FDA PMA, EUDAMED, PMDA, Health Canada Active Licence Listing, and UK MHRA PARMD query scope, and ProofShow operates the pipeline continuously, surfacing newly published medical-device regulatory-disclosure entries as they are issued and committed to the agency-disclosure infrastructure. The customer's marketing team receives a continuously refreshed library of regulatory-identifier-anchored, market-access-pathway-classified, medical-device-cleared product mentions that no marketing-elicited testimonial-collection program could ever match.
For the structural-format guidance that informs the testimonial-asset packaging stage, see the SBOM and VEX extraction guide, the SOC 2 and ISO 27001 extraction guide, the bug bounty extraction guide, the SEC filing extraction guide, and the patent filing extraction guide.